If the incretin class has the deepest human evidence in peptide science, the so-called repair peptides have the widest gap between reputation and record. BPC-157 and thymosin beta-4 (and its research fragment, TB-500) are discussed online with a confidence the literature does not yet support — which makes them the honest test of this series' method: report what investigators found, name the model it was found in, and say plainly what has never been shown.
BPC-157: a large animal literature, and almost no human one
BPC-157 is a synthetic 15-amino-acid fragment derived from a protective protein found in gastric juice. The published record is substantial in one specific sense: dozens of animal studies, largely from a University of Zagreb research group, spanning two decades.
What those investigators reported, in rodents: accelerated healing of transected Achilles tendon (Staresinic et al., Journal of Orthopaedic Research, 2003), improved recovery in muscle crush injury, protective effects on gastric and intestinal lesions, and effects on ligament healing — consistently in rat models, at researcher-controlled doses, with the investigators proposing angiogenic and growth-factor-mediated mechanisms.
What has not been published: a completed randomized human trial of BPC-157 for any indication. No phase 3, no phase 2 efficacy data in a peer-reviewed journal. The entire clinical reputation of this compound rests on animal findings plus anecdote. That does not make the animal work meaningless — it is genuine, peer-reviewed science, and it is why researchers remain interested. It makes the animal work animal work. As covered in Reading a Peptide Study, rodent doses do not scale to other species by body weight, and most compounds that look promising in rodents fail to replicate their effects in humans.
Thymosin beta-4: a real protein, a thin clinical record
Thymosin beta-4 is a naturally occurring 43-amino-acid protein involved in actin regulation, present in nearly all human cells and concentrated in wound fluid. The research interest is legitimate: published work includes dermal wound-healing studies in animals, corneal injury models, and early-phase human trials — RegeneRx's phase 2 programs in dermal and corneal wound healing reported safety and mixed efficacy signals, without progressing to approval.
"TB-500," the research-market name, typically refers to a synthetic fragment of the protein (commonly the 17–23 actin-binding region), which is a further step removed: much of the published biology concerns the full protein, not the fragment sold for research. A certificate can tell you a vial contains a peptide of the right mass; it cannot transfer the parent protein's literature to a fragment.
Why this class attracts the strongest claims
The repair peptides are where the community errors catalogued elsewhere on this site concentrate: rodent findings quoted as established effects, mg/kg doses transposed across species, and anecdotes standing in for the missing trials. The commercial incentive is obvious — recovery is a universal want, and the animal literature provides real citations to point at. The literature itself is more modest: promising, preclinical, unreplicated in humans, and stated as exactly that by most of the investigators who produced it.
What is established, and what is not
Established: a consistent body of peer-reviewed rodent evidence for BPC-157 across injury models; a real biological role for endogenous thymosin beta-4; early-phase human safety data for the full thymosin protein in wound indications.
Not established: any human efficacy outcome for BPC-157; clinical efficacy for thymosin beta-4 sufficient for approval in any indication; and any published human data at all for most of the fragments sold under research names.
No compound discussed here is FDA-approved. Nothing above is dosing guidance or a treatment claim. Research use only.
Sources include: Staresinic et al., J Orthop Res 2003; Sikiric et al., Current Pharmaceutical Design 2018 (review of the BPC-157 preclinical program); Goldstein et al., Annals of the NY Academy of Sciences 2010 (thymosin beta-4 biology); RegeneRx phase 2 program disclosures.
For research use only · Not for human or veterinary use · No compound discussed here is FDA-approved for any indication